-
公开(公告)号：US11130819B2
公开(公告)日：2021-09-28
申请号：US17228023
申请日：2021-04-12
Applicant: GENMAB A/S
Inventor： David Satijn , Esther C. W. Breij , Bart E. C. G. De Goeij , Kristel Kemper , Patrick Engelberts , Edward N. Van Den Brink , Rik Rademaker , Dennis Verzijl , Sjeng Horbach , Paul Parren
Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号：US20240392032A1
公开(公告)日：2024-11-28
申请号：US18617483
申请日：2024-03-26
Applicant: Genmab A/S
Inventor： David SATIJN , Esther C.W. Breij , Bart E.C.G. De Goeij , Kristel Kemper , Patrick Engelberts , Edward N. Van Den Brink , Rik Rademaker , Dennis Verzijl , Sjeng Horbach , Paul Parren
Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号：US11814437B2
公开(公告)日：2023-11-14
申请号：US17938523
申请日：2022-10-06
Applicant: GENMAB A/S
Inventor： David Satijn , Patrick Engelberts , Kristel Kemper , Esther C. W. Breij , Simone Oostindie , Farshid Alemdehy
CPC classification number: C07K16/2878 , A61P35/00 , C07K16/2809 , C12N15/63 , C07K2317/31 , C07K2317/526 , C07K2317/565
Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
-
Patent Agency Ranking
公开(公告)号：US11008399B2
公开(公告)日：2021-05-18
申请号：US17077376
申请日：2020-10-22
Applicant: GENMAB A/S
Inventor： David Satijn , Esther C. W. Breij , Bart E. C. G. De Goeij , Kristel Kemper , Patrick Engelberts , Edward N. Van Den Brink , Rik Rademaker , Dennis Verzijl , Sjeng Horbach , Paul Parren
Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号：US20240376221A1
公开(公告)日：2024-11-14
申请号：US18660672
申请日：2024-05-10
Applicant: Genmab A/S , BioNTech SE
Inventor： Kristel Kemper , Maarten van der Kroef , Dennis Verzijl , Andrea Gorlani , Pauline Linda de Goeje , Lars Guelen , David Satijn , Esther C. W. Breij , Ugur Sahin , Sina Fellermeier-Kopf , Maren Köhne
Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号：US11970544B2
公开(公告)日：2024-04-30
申请号：US17353087
申请日：2021-06-21
Applicant: GENMAB A/S
Inventor： David Satijn , Esther C. W. Breij , Bart E. C. G. De Goeij , Kristel Kemper , Patrick Engelberts , Edward N. Van Den Brink , Rik Rademaker , Dennis Verzijl , Sjeng Horbach , Paul Parren
CPC classification number: C07K16/30 , A61P35/00 , C12N15/79 , A61K2039/505 , C07K2317/31 , C07K2317/51 , C07K2317/565
Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号：US20240400703A1
公开(公告)日：2024-12-05
申请号：US18660847
申请日：2024-05-10
Applicant: Genmab A/S , BioNTech SE
Inventor： Kristel Kemper , Maarten van der Kroef , Dennis Verzijl , Andrea Gorlani , Pauline Linda de Goeje , Lars Guelen , David Satijn , Esther C. W. Breij , Ugur Sahin , Sina Fellermeier-Kopf , Maren Köhne
Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号：US20230132049A1
公开(公告)日：2023-04-27
申请号：US17938523
申请日：2022-10-06
Applicant: GENMAB A/S
Inventor： David SATIJN , Patrick Engelberts , Kristel Kemper , Esther C.W. Breij , Simone OOSTINDIE , Farshid ALEMDEHY
Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.012 seconds)
